Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
Epclusa
Read More
Epclusa ([sofosbuvir + velpatasvir]; Gilead) is a once-daily, fixed-dose combination of Gilead’s nucleotide NS5B polymerase inhibitor, sofosbuvir; and the company’s second-generation NS5A inhibitor, velpatasvir.
November 6, 2017
Find out more
Kynamro
Read More
Kynamro (mipomersen sodium) was the first antisense therapy to enter the dyslipidemia market. It is marketed by Kastle Therapeutics and is approved in the US for the treatment of homozygous familial hypercholesterolemia (HoFH).
June 22, 2018
Find out more
leronlimab
Read More
Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into host cells.
June 28, 2019
Find out more
fostemsavir
Read More
Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells.
June 28, 2019
Find out more
Keytruda
Read More
Keytruda is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.
February 26, 2020
Find out more
Mekinist
Read More
Mekinist (trametinib; Novartis/Japan Tobacco) is a selective allosteric inhibitor of the MEK1 and MEK2 enzymes in the mitogen-activated protein kinase (MAPK) pathway.
August 30, 2018
Find out more
Bronchitol
Read More
Bronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent.
September 3, 2018
Find out more
Betalutin
Read More
Betalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in B cells and B-cell lymphomas.
January 31, 2019
Find out more
Xarelto
Read More
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan.
March 15, 2018
Find out more
Lynparza
Read More
Lynparza (olaparib; AstraZeneca) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor. The PARP enzyme plays a central role in a number of cellular processes involved in cellular homeostasis.
February 26, 2020
Find out more
Kadcyla
Read More
Kadcyla (ado-trastuzumab emtansine; ImmunoGen/Roche/Chugai) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC), which contains the humanized anti-HER2 immunoglobulin G1 Herceptin.
March 9, 2015
Find out more
Delzicol/Asacol HD
Read More
This product profile relates to the mesalamine franchise that covers Delzicol (mesalamine; Actavis), Asacol (mesalamine; Zeria/Kyowa Hakko Kirin), and Asacol HD (mesalamine; Actavis/Zeria)…
May 1, 2015
Find out more
Ad26.RSV.preF
Read More
Ad26.RSV.preF, in development by Johnson & Johnson, is a replication-deficient vector vaccine that encodes a prefusion form of the RSV F protein.
October 5, 2018
Find out more
Rytary
Read More
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.
June 21, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *